Bendazac is an indazole derivative and a monocarboxylic acid, specifically an oxyacetic acid, used as an eye drop to treat cataracts (Bendazac Lysine Salt) and as a topical cream for dermatitis, eczema, hives, skin ulcers, and other inflammatory skin conditions. In addition to its anti-inflammatory, antinecrotic, choleretic, and antilipidemic properties, its primary function is to inhibit protein denaturation. This effect has been demonstrated to prevent the denaturation of various proteins, including ocular lens proteins, caused by heat, ultraviolet radiation, free radicals, and other chemicals. Consequently, this property has been proven particularly useful in managing and delaying the progression of cataracts. #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
Angelini Fine Chemicals
Fabbricazione di prodotti farmaceutici
Aprilia, Italy 4.045 follower
Angelini Fine Chemicals is the chemical business unit of Angelini Pharma SpA
Chi siamo
Angelini Fine Chemicals is the chemical business unit of Angelini Pharma SpA that is fully dedicated to cGMP third party manufacturing of Early & Adv. IMs, APIs and HPAPIs for the pharmaceutical and biotech industry. Located in the industrial outskirts of Aprilia (Southern Rome Area - Italy), with 70.000 m2 state-of-the-art cGMP manufacturing facility and R&D labs, Angelini Fine Chemicals is housing a vast range of synthetic and scale-up capabilities to advancing your chemical development and manufacturing programs – from early clinical lots up to commercial production, from 1-1000 kg up to multi-tons scale. With a continuous program of investment in R&D and novel chemical technologies (such as HPAPI and Flow Chemistry), Angelini Fine Chemicals is at forefront of development and manufacturing of custom small molecule APIs and HPAPIs over 50 years. Our “make-chemistry” attitude is valuable tool for originator pharmaceutical companies seeking an attractive and trustworthy CDMO business partner to expediting their R&D pipeline development-to-market. ANGELINI FINE CHEMICALS: YOUR CHEMISTRY IS OUR BUSINESS
- Sito Web
-
https://www.angelinifinechemicals.com/
Link esterno per Angelini Fine Chemicals
- Settore
- Fabbricazione di prodotti farmaceutici
- Dimensioni dell’azienda
- 51-200 dipendenti
- Sede principale
- Aprilia, Italy
- Tipo
- Società privata non quotata
- Data di fondazione
- 1967
- Settori di competenza
- Custom Development, cGMP Manufacturing, Advanced Intermediates, APIs e HPAPIs
Località
-
Principale
Via Guardapasso, 1
Aprilia, Italy 04011, IT
Dipendenti presso Angelini Fine Chemicals
Aggiornamenti
-
From 3rd to 6th September 2024 - Parsippany Hilton, Parsippany, NJ - Our colleague Gary Conte will also be in attendance! Schedule an appointment with him 👇 [email protected] #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
-
-
The international pharmaceutical company Angelini Pharma, part of Angelini Industries, is committed to find innovative health solutions. Angelini Fine Chemicals is its fine chemical business subsidiary, fully dedicated to the development and production of APIs, small molecules for the global pharmaceutical market. We are based in Aprilia, Southern Rome area, with a 70,000 m2 state-of-the-art laboratory production facility. Our aim is to help pharmaceutical customers advance their drug development programs from early clinical stages to commercial production, from one kilogram to multiple tons. Find out all the details here 👇 https://lnkd.in/dinTa_iK #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
-
-
👉 What trend do you see in the HPAPI Industry? "HPAPIs are becoming a lot more common and with their ability to target specific cells and minimize off-target toxicity, antibody-drug conjugates (ADCs) are being leveraged to treat serious diseases including the cancer treatment area. Pharmaceutical companies are always looking for ways to stay competitive, often by improving upon what is already on the market. Higher potency drugs have the potential to achieve similar efficacy at a lower dose than other APIs, which is appealing to drug developers because it minimizes patient exposure to medication as a result , most oncological agents are HPAPIs, and we are seeing increasing clients with those types of compounds." 👉 Ongoing research points to new developments in payloads and linkers. How does Angelini expect this to impact the market? "The impact of novel payloads and improved linker chemistry will be the future. We will start to see more and more of these newer generation products hitting later phases and every new wave should bring differentiating advantages. From a R&D perspective, you need the technological expertise to support these new developemnts which we have at Angelini." 👉 Where do you see the strengths in Angelini Fine Chemicals (AFC) and HPAPI’s production? "We operate GMP production suites for gram-scale and multi-kilogram production capacity at our site. We have seen two fronts that have gradually become more and more established over time: Processing protocols: Having quality management and environmental health and safety teams involved in every step of production is critical to maintaining the highest quality standards when using HPAPIs: procedures mandate that safety assessments, cleaning validation requirements, and handling instructions be in place before any new substance is put on manufacturing or dispensing equipment. Flexible and agile manufacturing: The rapidly changing environment of HPAPI drug development requires flexibility in manufacturing so that production lines can change volumes, processes, and products to meet changing market demands or clinical trial requirements." 👉 How does AFC offer solutions for HPAPI manufacturing? "The completed HPAPI capacity expansion covers the addition of two new cGMP kilo-lab suites fully dedicated to the development of small and mid-scale cGMP manufacturing of custom HPAPIs (at high containment levels of OEB5 & OEB6). This new platform offers all scales of HPAPI manufacture across the full OEL / OEB band spectrum to meet a wide range of pharmaceutical outsourcing services, from route selection/proof of concept runs to scale-up (up to small- and large-volume HPAPI cGMP manufacturing.) At AFC we believe this mirrors the trends in HPAPi drug development including ADCs" #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
-
-
Angelini Fine Chemicals presents: Tommaso Iacoangeli, Project Manager Have a good job Tommaso. We are a great team 😁 #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
-
-
Welcome to BOS BASEL 2024 - Basel, Switzerland We are ready to meet you! It's a great opportunity to speak with our colleague Carlo Lusso on site! ✏️ [email protected] #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
-
-
It has been a busy and eventful six months: we have participated in trade shows and events, come in contact with many new customers, and kept up-to-date with all the latest industry news. We are definitely ready to face the second half of the year! #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
-
-
On June 19th and 20th in Basel, Switzerland, we will be present in BOS BASEL 2024. The focus of BOS Basel 2024 is mainly on outsourcing CMCs under development for small molecules and biologic drugs, as well as covering new therapeutic entities. We are ready to welcome all news! Schedule an appointment with our colleague Carlo Lusso ✏️ [email protected] #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
-
-
Here we are in Boston at ADC Payload Summit - from 21 May to 23 May 2024. It's a great opportunity to meet our colleague Gary Conte on site! 👉 Gary Conte [email protected] #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
-
-
High Potent Medicines Conference, May 22-24, Assago, Milano. It's a great opportunity to meet our colleague Carlo Lusso on site! Write an email to him👉[email protected] #AngeliniFineChemicals #PutYourChemistryInOurHands #JoinOurFuture
-